ANDA 213132, held by Glenmark Pharmaceuticals. Arformoterol Tartrate.
As of Nov 21, 2026, ANDA 213132 (Arformoterol Tartrate), held by Glenmark Pharmaceuticals, was first approved by FDA on Jun 22, 2021, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 22, 2021 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Arformoterol TartrateEQ 0.015MG BASE/2ML · solution;inhalation | Arformoterol Tartrate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters